ATEKA ZAKI: Open Payments
NPI 1053321042 · RICHMOND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,059 in 148 payments from 19 companies in 2025. Trend: 2023 $2,904 · 2024 $2,025 · 2025 $3,059
Food & beverage: $2,909Education: $150
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $454 |
| Otsuka America Pharmaceutical, Inc. | 20 | $445 |
| Axsome Therapeutics, Inc. | 18 | $331 |
| ABBVIE INC. | 19 | $268 |
| Vanda Pharmaceuticals Inc. | 12 | $259 |
| Teva Pharmaceuticals USA, Inc. | 7 | $234 |
| Alkermes, Inc. | 11 | $213 |
| Bausch Health US, LLC | 12 | $190 |
| Corium, LLC | 8 | $165 |
| E.R. Squibb & Sons, L.L.C. | 8 | $157 |
Products named: CAPLYTA, Auvelity, VRAYLAR, FANAPT, REXULTI, ARISTADA, APLENZIN, Azstarys.
Industry payments across TX — which companies pay providers there.
